Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Improving AML outcomes

Charles Craddock • 26 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia Cyclophosphamide
COSI

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, gives an overview of what we can expect to see from future acute myeloid leukemia (AML) clinical trials in the UK and how patient outcomes can be improved with the ongoing research that is currently underway. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Charles Craddock

Strategies to reduce relapse risk post-transplant in AML
11:48
Strategies to reduce relapse risk post-transplant in AML
Charles Craddock • 19 Sep 2026
Expanding donor access for allogeneic transplantation in AML
2:46
Expanding donor access for allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026
Allogeneic transplantation in fit older adults with AML
1:34
Allogeneic transplantation in fit older adults with AML
Charles Craddock • 19 Sep 2026
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
1:35
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals